Session date: 
06/19/2019 - 12:00pm to 1:00pm EDT

James L. Gulley, M.D., Ph.D., F.A.C.P.

Chief, Genitourinary Malignancies Branch

Head, Immunotherapy Group, GMB

Director, Medical Oncology Service

Center for Cancer Research, NCI, NIH


Dr. James Gulley is an internationally recognized expert in immunotherapy for cancer. He graduated from Loma Linda University in California with a PhD in microbiology in 1994 and an MD in 1995. As part of this eight-year MD/PhD Medical Scientist Training Program, he completed a dissertation on tumor immunology. He completed his residency in Internal Medicine at Emory University in 1998, followed by a Medical Oncology fellowship at the National Cancer Institute (NCI). 


Dr. Gulley serves within the Center for Cancer Research (CCR) of the National Cancer Institute as Chief of the Genitourinary Malignancies Branch (GMB), the Director of the Medical Oncology Service (CCR), and also Head of the Immunotherapy Section within the GMB. He has been instrumental in the clinical development a number of therapeutic cancer vaccines. In addition, he serves as the coordinating Principle Investigator (PI) of several international trials of immunotherapies, one of which led to FDA approval of an immunotherapy called Avelumab. 


Dr. Gulley has received numerous awards including the Presidential Early Career Award for Scientists and Engineers (PECASE), the highest award bestowed by the US government on outstanding scientists early in their careers.  Dr. Gulley serves on many national and NIH boards and committees. He has been an investigator on more than 120 clinical trials, authored more than 250 scientific papers or chapters, serves on a number of editorial boards of scientific journals and has made hundreds of presentations at national / international meetings.

Bluemle Life Sciences Building
233 South 10th Street
Conference Room 101
Philadelphia, PA 19107
United States
Session Summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Attendance

Please login or register to take this course.